Atreca Inc

BCEL

NASDAQ. Currency in USD

0.91 +0.04 ( +4.01% )

Real time prices: December 09

Market Cap.
35.54M
Beta (5Y monthly)
0.58
Price/Earnings
-
EPS (TTM)
-2.76
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
152,035
1y Target Est.
12.00
Day's Range
0.87
-
0.93
52 Week's Range
0.85
-
5.36

Historical Summary

Performance
EPS growth
Share Buybacks

About Atreca Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.atreca.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
30.44M
Employees
91
Address
835 Industrial Road, South San Francisco, CA, United States, 94070
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Latest news

Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday

Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. Elevate...
By Benzinga - 3 weeks ago

Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022...
By GlobeNewswire Inc. - 4 weeks ago

Atreca to Present at Upcoming Investor Conferences
Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a...
By GlobeNewswire Inc. - 4 weeks ago

Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a...
By GlobeNewswire Inc. - 9 weeks ago

Atreca to Present at Upcoming Investor Conferences
Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a...
By GlobeNewswire Inc. - 13 weeks ago

Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a...
By GlobeNewswire Inc. - 17 weeks ago

Atreca to Present at Upcoming Investor Conferences
Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a...
By GlobeNewswire Inc. - 18 weeks ago